VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
XLO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
XLOXilio Therapeutics, Inc.
$7.54$50M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksXLOCash Flow

Xilio Therapeutics, Inc. (XLO) Cash Flow Statement

7Y historyFree accessUpdated daily

Operating cash flow was -$18.8M in 2026Q2 and free cash flow margin was -100.5%, with cash burn largely funded by a $136.0M cash balance rather than internally generated cash.

Income StatementBalance SheetCash FlowRatios

XLO Cash Flow Statement

Annual statement

XLO Cash Flow Statement

Xilio Therapeutics, Inc. (XLO) cash flow statement — 7-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Cash from Operations-56.9M-4.99M-18.38M-68.62M-75.72M-80.75M-36.09M-17.84M
Operating CF Margin %--11.41%-289.69%-----
Operating CF Growth %-99.66%72.84%73.22%9.38%6.23%-123.74%-102.27%-
Net Income-11.49M-35.04M-58.24M-76.4M-88.22M-75.8M-55.22M-17.31M
Depreciation & Amortization1.32M1.54M1.64M1.9M1.85M1.5M1.06M240K
Stock-Based Compensation8.66M6.94M6.43M7.38M8.42M4.96M1.3M112K
Deferred Taxes00000222K0-1.74M
Other Non-Cash Items-23.77M-3.56M3K160K224K173K165K56K
Working Capital Changes-31.61M25.13M31.78M-1.66M2M-11.8M16.6M797K
Change in Receivables22.5M-5M000000
Change in Inventory00000000
Change in Payables-1.54M152K1.53M-2.06M485K-2.82M2.93M970K
Cash from Investing-728K-518K-36K-486K-1.87M-1.1M-2.19M-715K
Capital Expenditures-728K-518K-36K-486K-1.87M-1.1M-2.19M-715K
CapEx % of Revenue1.32%1.18%0.57%-----
Acquisitions00000000
Investments--------
Other Investing00000000
Cash from Financing76.07M87.78M29.2M-6.55M-69K260.67M10.03M60.02M
Debt Issued (Net)00-3.38M-6.75M-85K-110K-99K9.95M
Equity Issued (Net)77.62M87.78M6.83M202K16K261.25M9.97M60.02M
Dividends Paid00000000
Share Repurchases00000000
Other Financing-1.55M025.75M00-467K159K-9.95M
Net Change in Cash18.44M82.27M10.78M-75.68M-77.67M178.82M-28.25M41.46M
Free Cash Flow-57.63M-5.51M-18.41M-69.11M-77.59M-81.85M-38.28M-18.56M
FCF Margin %-104.75%-12.59%-290.26%-----
FCF Growth %-227.79%70.08%73.35%10.93%5.21%-113.83%-106.27%-
FCF per Share-2.93-0.66-4.82-35.19-39.65-204.40-1023.15-634.77
FCF Conversion (FCF/Net Income)5.02x0.14x0.32x0.90x0.86x1.07x0.65x1.03x
Interest Paid0062K00492K536K14K
Taxes Paid00000000

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Cash burn against lumpy receipts

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Operating Cash Diverges From Reported Earnings

Based on the reported quarterly figures, XLO's operating cash flow tracked net income in direction only intermittently, with the ratio swinging from roughly -2.18 in 2025Q1 to 2.94 in 2026Q2, which signals earnings that are poorly anchored to cash generation.

The 2025Q1 quarter shows positive operating cash flow of $29.0M against a net loss of $13.3M, while 2026Q2 shows operating cash outflow of $18.8M against a net loss of $6.4M, so the conversion ratio is driven more by working capital timing than by underlying profitability. Net income in 2025Q4 of $10.4M was accompanied by operating cash outflow of $2.0M, a pattern that suggests reported profit is largely non-cash or collaboration-recognition driven. Investors should monitor whether future cash receipts from collaborations actually arrive in line with recognized revenue, as the current data does not establish that link.

Persistent Free Cash Outflow Despite Episodic Inflows

As reported in the cash flow statements, XLO generated free cash flow of only $29.0M in 2025Q1 against outflows of $10.5M to $22.9M in most other quarters, leaving the ten-quarter trajectory net negative.

Free cash flow margins are deeply negative in most periods, reaching -181.0% in 2026Q1 and -100.5% in 2026Q2 on the reported revenue base, indicating that operating spend is not being covered by collaboration income. The single positive quarter appears to reflect a large working capital release rather than a durable shift in cash economics. Without that release, the business shows a consistent monthly burn profile that warrants close monitoring of runway.

Working Capital Swings Drive Quarterly Results

Based on the reported figures, working capital changes ranged from a $40.2M inflow in 2025Q1 to a $36.3M outflow in 2024Q3, and these swings account for most of the quarter-to-quarter variance in operating cash flow.

The magnitude of working capital movements relative to net income suggests that receivables, deferred revenue, or accrued liabilities are the primary cash timing mechanism rather than operating efficiency. The 2026Q2 working capital outflow of $19.9M, following a $12.1M outflow in 2026Q1, indicates cash absorption that is accelerating rather than reversing. The data does not isolate the individual components, so the specific driver remains unclear and warrants further investigation.

Minimal Capital Intensity Through the Period

As reported in the cash flow data, XLO's capital expenditure remained below $0.6M in every quarter, with CapEx-to-revenue ratios of 0.1% to 5.0%, reflecting an asset-light research model.

Low capital intensity is consistent with a clinical-stage biotechnology profile in which cash consumption is driven by R&D rather than physical assets. Depreciation and amortization of roughly $0.3M to $0.5M per quarter is similarly modest, so maintenance requirements do not appear to weigh on cash flow. The implication is that cash burn is an operating expense question, not a capital allocation one.

Stock-Based Compensation Flatters Cash Burn

Based on the reported figures, stock-based compensation of $1.1M to $2.9M per quarter is a non-cash add-back, so the reported operating cash burn understates the economic cost of employee compensation.

Because SBC is excluded from operating cash flow, shareholders bear a dilution cost that does not appear in the cash burn figures, which may make the business look less expensive than it is on an owner-economics basis. The working capital inflows that offset burn in certain quarters may also reflect timing of collaboration receipts rather than sustainable cash generation. Investors should weigh these items together when judging runway, and should not treat the single positive cash quarter as evidence of self-funding capacity.

XLO — Frequently Asked Questions

Quick answers to the most common questions about buying XLO stock.

How much cash does Xilio Therapeutics, Inc. (XLO) generate from operations?

Xilio Therapeutics, Inc. (XLO) generated $-5.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Xilio Therapeutics, Inc.'s free cash flow?

Xilio Therapeutics, Inc. (XLO) reported negative free cash flow of $5.5M in 2025, indicating capital requirements exceeded cash from operations.

What is Xilio Therapeutics, Inc.'s capital expenditure (CapEx)?

Xilio Therapeutics, Inc. (XLO) spent $0.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.